Collagen Matrix Inc., a leader in regenerative medicine, global manufacturer of collagen and mineral-based medical devices, and Linden Capital Partners portfolio company, announced today the appointment of Timothy J. Scannell to its board of directors. A seasoned and dynamic medical device leader, Mr. Scannell most recently served as President and Chief Operating Officer of Stryker.
Timothy J. Scannell brings 30 years of success and leadership from his broad experience at Stryker, one of the world’s leading medical technology companies. During his time as President and C.O.O., Mr. Scannell was responsible for all commercial businesses and regions globally for Stryker and delivered market-leading results. During his early career, Mr. Scannell led Stryker’s neurotechnology, spine, and medsurg businesses. Additionally, he served as general manager of Stryker’s biotech division. Mr. Scannell currently serves as Chair of Insulet Corporation’s board of directors. He also serves on the board of directors for Novocure.
“Tim’s appointment represents a meaningful addition to our board, and I look forward to the strength and experience he will bring to the table” said Shawn McCarthy, President and Chief Executive Officer of Collagen Matrix, Inc. “He joins Collagen Matrix at an exciting time as we continue to accelerate our growth strategy and further our vision of improving patient lives through innovative regenerative devices. We are confident that Tim’s diversified leadership experience and proven track record will provide valuable perspective.”
Mr. Scannell holds a Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame.
